Lyme Disease Diagnostics Market at US$ 2 Bn in 2022 and is projected to expand at a CAGR of 4% from 2022 to 2030

Lyme Disease Setting Record in Number of Cases Every Year

Lyme disease is the most prevalent vector-borne disease across the world. It is caused by the bacterium Borrelia burgdorferi and sometimes, Borrelia mayonii. Lyme disease is diagnosed based on symptoms, physical findings (e.g., rash), and the possibility of exposure to infected ticks. Lyme disease diagnostics measure Borrelia immunizers in the blood, or the cerebrospinal fluid (CSF) to identify the signs and symptoms of central nervous system disease. The surge in the frequency and prevalence of Lyme disease and rising investments from government organizations and large corporates for developing diagnostic kits are primary reasons contributing to the growth of the global Lyme disease diagnostics market.

Get the sample copy of report@ https://qyresearchmedical.com/sample/111532

Healthcare organizations such as CDC suggests two methods to identify these immunizers or antibodies to confirm a diagnosis of Lyme disease. The first diagnosis use practices such as an enzyme immunoassay (EIA) or immunofluorescence (IFA) method to measure Borrelia IgM and/or IgG antibodies. This diagnosis is intended to be very sensitive so that it will detect as many cases of Lyme disease as possible. The results may be positive even with similar types of bacteria such as the different tick-borne disease or syphilis or in other conditions, such as Lupus. The second diagnosis is recommended after the test of initial diagnosis with positive or indeterminate results. It is called a Western Blot that detects specific antibodies to multiple antigens to confirm the findings.

Lyme disease cases are presently crossing the 400,000 mark every year in U.S. alone, and the need for diagnosis of these patients is rapidly increasing, thus proving propitious for the global Lyme disease diagnostics market.

Similarities Between Borrelia Burgorferi, SARS-CoV-2 Proving Challenging for Experts

The worldwide COVID-19 pandemic has eclipsed the attention of healthcare professionals, affecting all areas of health and diagnostics care. The crisis has had several indirect health effects as well. The concern among individuals for the infection has decreased outpatient visits with healthcare providers. Symptomatic patients may be considered to have COVID-19 until negative test results are received, implying that evaluations for other diseases will be delayed, potentially leading to adverse outcomes. People with Lyme disease symptoms were asked to postpone their tests, as the coronavirus spread began to take over the world. People were recommended to be in quarantine as evaluation for other causes of the patient’s symptoms other than the COVID-19 virus was often deferred, risking delayed diagnosis and complications. Moreover, as Lyme and COVID-19 virus often start with non-specific flu-like symptoms with fever, headache, and general achiness and fatigue, it made patients and medical experts more concerned about both infections in individuals. Thus, patients were suggested to diagnose with the available medical institutions helping to diagnose other diseases.

View full report@ https://qyresearchmedical.com/report/lyme-disease-diagnostics-market-diagnostic-test-serological-test-polymerase-chain-reaction-pcr-testing-immunofluorescence-ifa-lymphocyte-transformation-test-urine-antigen-testing-and-others-sample-blood-2021-2031/111532

The impact of this dramatic change in healthcare provision is only opening to be recognized, but includes decreased ambulatory visits with outpatient providers, hampering the growth of the global Lyme disease diagnostics market. In addition, the COVID-19 crisis has led to the adoption of telemedicine for the delivery of healthcare in many developed regions including North America and Europe. However, the impact of telemedicine on the diagnosis of acute infectious diseases such as Lyme disease is still under observation. Furthermore, misdiagnosis and delays in diagnosis of Lyme disease can potentially result in bacterial dissemination and involvement of distant organ systems, most importantly the neurologic, cardiac, and musculoskeletal systems. The neurologic association normally exhibits after the first few weeks of untreated virus and can result in meningitis, cranial nerve palsy, and radiculoneuritis. Post-COVID, however, there is likely to be a significant increase in the diagnosis of Lyme disease, as the number of vaccination is increasing, most people can feel safe to visit a diagnostics center. This is expected to propel the Lyme disease diagnostics market.

New Ways to Diagnose Lyme Disease to Drive Global Demand for Diagnostics

The advancement in research and diagnosis of a new cytokine-based immunoassay for Lyme diagnosis can allow for earlier and more rapid diagnosis of the Lyme disease, if successful. Numerous researchers are working on the progress of a new, rapid point-of-care Lyme diagnostic test using lateral flow technologies. Metabolic biomarkers and biosignatures for enhanced diagnostics are being recognized and defined. All these studies are expected to contribute to new ways for identifying the Lyme disease, earlier-stage diagnosis, accurate staging of disease, or indications of successful treatment. This is anticipated to fuel the growth of the Lyme disease diagnostics market.

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111532/2900

The advancements in the Lyme disease diagnostics portfolio by several major businesses have welcomed the approval by launching innovative Lyme disease diagnostics. T2 Biosystems developed a T2Lyme Panel diagnostic technique for the detection of Lyme disease-causing bacteria. Such innovations are likely to fuel the demand for upgraded Lyme disease diagnostics, thus driving the Lyme disease diagnostics market.

In the initial stages of diagnosis, researchers can now look at other molecules that arise earlier in infection instead of waiting for the antibodies creation in the blood. The experts are examining the pattern of a host of non-antibody molecules, or biomarkers that rise in response to B. burgdorferi infection, as compared to the pattern in other disease overlapping symptoms with Lyme disease. The pattern distinguishes early Lyme disease from the different illnesses examined, and could precisely diagnose the disease even in clinical samples that had tested negative by the current immunologic assay. In most cases, antibiotics are used to treat Lyme disease. It can help recover quickly and more completely the sooner the treatment begins.

Furthermore, North America holds the most number of major diagnostics centers and key market players. Rising healthcare expenditure, early availability of new products, and major patient base in the U.S. are expected to dominate the regional shares in the Lyme disease diagnostics market during the forecast period.

Analysts’ Viewpoint

The world has witnessed a rising number of Lyme disease cases in recent years, and expected to further grow with increasing worldwide population. People living in wooded areas are more likely to undergo Lyme disease tests. In addition, with the rising cases of tick-borne infectious diseases and increasing incidences of new types of vector-borne diseases, the demand for new diagnostics centers and improved diagnostics is gradually rising favoring the global Lyme disease diagnostics market. However, a lack of awareness about distinct infections and Lyme disease diagnostics in several developing economies is expected to hamper the market growth to some extent. Nevertheless, rising healthcare investments in such regions and increasing health consciousness among people are most likely to expand the global Lyme disease diagnostics market during the forecast period.

Lyme Disease Diagnostics Market: Overview

Lyme disease, commonly known as Lyme borreliosis, is an infectious disease that is caused by Borrelia bacteria and carried by ticks. The most typical indication of infection is the spreading red rash, known as erythema migrans, which emerges around a week after tick bite.

Blood, cerebrospinal fluid (CSF), joint fluid, and urine are used for the diagnosis of Lyme disease

The global Lyme disease diagnostics market has experienced significant growth in the past decade due to increase cases of Lyme disease

Various diagnostic tests are available for the detection of Lyme disease, including serological test, polymerase chain reaction (PCR) testing, immunofluorescence (IFA), lymphocyte transformation test, urine antigen testing, and others

Increase in incidences and prevalence of Lyme disease drive the demand for Lyme disease diagnostics. Lyme disease is a highly common vector-borne disease in the U.S. and across the globe, with over 400,000 new cases every year. Only a few tests are available in the market that accurately diagnose Lyme disease. Moreover, frequent mutations and genotypic variations in the causative bacteria increase the prevalence among the global population.

Need of development of novel therapy has increased due to various disadvantages associated with conventional and regular traditional techniques such as lack of accuracy, precision, and reproducibility

Various research institutes, organizations, and healthcare companies are engaged in finding a better technology for the diagnosis of Lyme disease, which, in turn, drives the global Lyme disease diagnostics market

Expansion of Lyme disease diagnostics portfolio by key companies boosts the approval and launch of innovative Lyme disease diagnostics. In September 2018, T2 Biosystems, Inc. developed T2Lyme Panel diagnostic technique for detection of Lyme disease-causing bacteria.

Market Segmentation: Lyme Disease Diagnostics Market

In terms of diagnostic test, the global Lyme disease diagnostics market has been classified into serological test, polymerase chain reaction (PCR) testing, immunofluorescence (IFA), lymphocyte transformation test, urine antigen testing, and others. The serological test segment has been split into ELISA and Western blot. The serological test segment is anticipated to dominate the global Lyme disease diagnostics market during the forecast period.

Based on sample, the global Lyme disease diagnostics market has been categorized into blood, cerebrospinal fluid (CSF), joint fluid, and urine. The blood segment dominated the global Lyme disease diagnostics market in terms of revenue in 2020.

In terms of end user, the global Lyme disease diagnostics market has been divided into hospitals, clinical laboratories, physician clinics, and others. The clinical laboratory segment dominated the global Lyme disease diagnostics market in terms of revenue in 2020.

Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The report provides current and expected revenue (US$ Mn) for each of these segments from 2017 to 2031, considering 2020 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2021 to 2031, along with market size estimations.

Regional Overview: Lyme Disease Diagnostics Market

In terms of region, the global Lyme disease diagnostics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.

Current and expected market revenue (US$ Mn) of these regional markets and their major countries have been provided in the report from 2017 to 2031, with their CAGRs from 2021 to 2031

The study also offers a list of recommendations, highlights, and useful insights of the global Lyme disease diagnostics market, which would help new companies willing to enter the market and existing companies to increase market shares and in the decision-making process

Major Players

The Lyme disease diagnostics market report concludes with the company profiles section, which includes key information about major players in the global Lyme disease diagnostics market

Leading players analyzed in the Lyme disease diagnostics market report include

  • T2 Biosystems, Inc.
  • QIAGEN
  • DiaSorin S.p.A
  • Bio-Rad Laboratories
  • Thermo Fisher Scientific, Inc.
  • Trinity Biotech plc
  • IGeneX Inc.
  • Lyme Diagnostics Ltd.
  • PerkinElmer Inc.
  • Oxford Immunotec plc (Boulder Diagnostics)
  • Cenogenics Corporation
  • Quest Diagnostics
  • Ceres Nanosciences, Inc.
  • Galaxy Diagnostics

Each of these players has been profiled in the Lyme disease diagnostics market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments

Key Questions Answered in Lyme Disease Diagnostics Market Report

  • What is the sales/revenue generated by Lyme disease diagnostics across all regions during the forecast period?
  • What are the opportunities in the global Lyme disease diagnostic market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which diagnostic test segment is expected to generate the highest revenue globally in 2031? Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Lyme Disease Diagnostics Market – Segmentation

Diagnostic Test

  • Serological Test
  • ELISA
  • Western Blot
  • Polymerase Chain Reaction (PCR) Testing
  • Immunofluorescence (IFA)
  • Lymphocyte Transformation Test
  • Urine Antigen Testing
  • Others

Sample

  • Blood
  • Cerebrospinal Fluid (CSF)
  • Joint Fluid
  • Urine

End User

  • Hospitals
  • Clinical Laboratories
  • Physician Clinics
  • Others

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

TABLE OF CONTENT

1. Preface

1.1. Report Scope and Market Segmentation

1.2. Research Highlights

2. Assumptions and Research Methodology

2.1. Assumptions and Acronyms Used

2.2. Research Methodology

3. Executive Summary

4. Market Overview

4.1. Introduction

4.2. Key Industry Developments

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunity

4.4. Global Lyme Disease Diagnostics Market Forecast

4.5. Global Lyme Disease Diagnostics Market Outlook

5. Market Outlook

5.1. Lyme Disease Epidemiology

5.2. Regulations Related to Lyme Disease

5.3. COVID-19 Pandemic Impact on Lyme Disease Diagnostics Industry

5.4. Key Industry Development

6. Global Lyme Disease Diagnostics Market Analysis, by Diagnostic Test

6.1. Introduction

6.2. Global Lyme Disease Diagnostics Market Value Share Analysis, by Diagnostic Test

6.3. Global Lyme Disease Diagnostics Market Forecast, by Diagnostic Test

6.3.1. Serological Test

6.3.1.1. ELISA

6.3.1.2. Western Blot

6.3.2. Polymerase Chain Reaction (PCR) Testing

6.3.3. Immunofluorescence (IFA)

6.3.4. lymphocyte Transformation Test

6.3.5. Urine Antigen Testing

6.3.6. Others

6.4. Global Lyme Disease Diagnostics Market Analysis, by Diagnostic Test

6.5. Global Lyme Disease Diagnostics Market Attractiveness Analysis, by Diagnostic Test

7. Global Lyme Disease Diagnostics Market Analysis, by Sample

7.1. Introduction

7.2. Global Lyme Disease Diagnostics Market Value Share Analysis, by Sample

7.3. Global Lyme Disease Diagnostics Market Forecast, by Sample

7.3.1. Blood

7.3.2. Cerebrospinal Fluid (CSF)

7.3.3. Joint Fluid

7.3.4. Urine

7.4. Global Lyme Disease Diagnostics Market Analysis, by Sample

7.5. Global Lyme Disease Diagnostics Market Attractiveness Analysis, by Sample

8. Global Lyme Disease Diagnostics Market Analysis, by End-user

8.1. Introduction

8.2. Global Lyme Disease Diagnostics Market Value Share Analysis, by End-user

8.3. Global Lyme Disease Diagnostics Market Forecast, by End-user

8.3.1. Hospitals

8.3.2. Clinical Laboratories

8.3.3. Physician Clinics

8.3.4. Others

8.4. Global Lyme Disease Diagnostics Market Analysis, by End-user

8.5. Global Lyme Disease Diagnostics Market Attractiveness Analysis, by End-user

9. Global Lyme Disease Diagnostics Market Analysis, by Region

9.1. Global Lyme Disease Diagnostics Market Scenario, by Region/Country

9.2. Global Lyme Disease Diagnostics Market Value Share and Attractiveness Analysis, by Region

9.3. Global Lyme Disease Diagnostics Market Forecast, by Region

9.3.1. North America

9.3.2. Europe

9.3.3. Asia Pacific

9.3.4. Latin America

9.3.5. Middle East & Africa

10. North America Lyme Disease Diagnostics Market Analysis

10.1. North America Lyme Disease Diagnostics Market Overview

10.2. North America Lyme Disease Diagnostics Market Value Share Analysis, Diagnostic Test

10.3. North America Lyme Disease Diagnostics Forecast, by Diagnostic Test

10.3.1. Serological Test

10.3.1.1. ELISA

10.3.1.2. Western Blot

10.3.2. Polymerase Chain Reaction (PCR) Testing

10.3.3. Immunofluorescence (IFA)

10.3.4. lymphocyte Transformation Test

10.3.5. Urine Antigen Testing

10.3.6. Others

10.4. North America Lyme Disease Diagnostics Market Attractiveness Analysis, by Diagnostic Test

10.5. North America Lyme Disease Diagnostics Market Analysis, by Sample

10.6. North America Lyme Disease Diagnostics Market Forecast, by Sample

10.6.1. Blood

10.6.2. Cerebrospinal Fluid (CSF)

10.6.3. Joint Fluid

10.6.4. Urine

10.6.5. Others

10.7. North America Lyme Disease Diagnostics Market Attractiveness Analysis, by Sample

10.8. North America Lyme Disease Diagnostics Market Analysis, by End-user

10.9. North America Lyme Disease Diagnostics Market Forecast, by End-user

10.9.1. Hospitals

10.9.2. Clinical Laboratories

10.9.3. Physician Clinics

10.9.4. Others

10.10. North America Lyme Disease Diagnostics Market Attractiveness Analysis, by End-user

10.11. North America Lyme Disease Diagnostics Market Value Share and Attractiveness Analysis, by Country

10.12. North America Lyme Disease Diagnostics Market Forecast, by Country

10.12.1. U.S.

10.12.2. Canada

11. Europe Lyme Disease Diagnostics Market Analysis

11.1. Europe Lyme Disease Diagnostics Market Overview

11.2. Europe Lyme Disease Diagnostics Market Value Share Analysis, Diagnostic Test

11.3. Europe Lyme Disease Diagnostics Forecast, by Diagnostic Test

11.3.1. Serological Test

11.3.1.1. ELISA

11.3.1.2. Western Blot

11.3.2. Polymerase Chain Reaction (PCR) Testing

11.3.3. Immunofluorescence (IFA)

11.3.4. lymphocyte Transformation Test

11.3.5. Urine Antigen Testing

11.3.6. Others

11.4. Europe Lyme Disease Diagnostics Market Attractiveness Analysis, by Diagnostic Test

11.5. Europe Lyme Disease Diagnostics Market Analysis, by Sample

11.6. Europe Lyme Disease Diagnostics Market Forecast, by Sample

11.6.1. Blood

11.6.2. Cerebrospinal Fluid (CSF)

11.6.3. Joint Fluid

11.6.4. Urine

11.7. Europe Lyme Disease Diagnostics Market Attractiveness Analysis, by Sample

11.8. Europe Lyme Disease Diagnostics Market Analysis, by End-user

11.9. Europe Lyme Disease Diagnostics Market Forecast, by End-user

11.9.1. Hospitals

11.9.2. Clinical Laboratories

11.9.3. Physician Clinics

11.9.4. Others

11.10. Europe Lyme Disease Diagnostics Market Attractiveness Analysis, by End-user

11.11. Europe Lyme Disease Diagnostics Market Value Share and Attractiveness Analysis, by Country/Sub-region

11.12. Europe Lyme Disease Diagnostics Market Forecast, by Country/Sub-region

11.12.1. Germany

11.12.2. France

11.12.3. U.K.

11.12.4. Italy

11.12.5. Spain

11.12.6. Rest of Europe

12. Asia Pacific Lyme Disease Diagnostics Market Analysis

12.1. Asia Pacific Lyme Disease Diagnostics Market Overview

12.2. Asia Pacific Lyme Disease Diagnostics Market Value Share Analysis, Diagnostic Test

12.3. Asia Pacific Lyme Disease Diagnostics Forecast, by Diagnostic Test

12.3.1. Serological Test

12.3.1.1. ELISA

12.3.1.2. Western Blot

12.3.2. Polymerase Chain Reaction (PCR) Testing

12.3.3. Immunofluorescence (IFA)

12.3.4. lymphocyte Transformation Test

12.3.5. Urine Antigen Testing

12.3.6. Others

12.4. Asia Pacific Lyme Disease Diagnostics Market Attractiveness Analysis, by Diagnostic Test

12.5. Asia Pacific Lyme Disease Diagnostics Market Analysis, by Sample

12.6. Asia Pacific Lyme Disease Diagnostics Market Forecast, by Sample

12.6.1. Blood

12.6.2. Cerebrospinal Fluid (CSF)

12.6.3. Joint Fluid

12.6.4. Urine

12.7. Asia Pacific Lyme Disease Diagnostics Market Attractiveness Analysis, by Sample

12.8. Asia Pacific Lyme Disease Diagnostics Market Analysis, by End-user

12.9. Asia Pacific Lyme Disease Diagnostics Market Forecast, by End-user

12.9.1. Hospitals

12.9.2. Clinical Laboratories

12.9.3. Physician Clinics

12.9.4. Others

12.10. Asia Pacific Lyme Disease Diagnostics Market Attractiveness Analysis, by End-user

12.11. Asia Pacific Lyme Disease Diagnostics Market Value Share and Attractiveness Analysis, by Country/Sub-region

12.12. Asia Pacific Lyme Disease Diagnostics Market Forecast, by Country/Sub-region

12.12.1. Japan

12.12.2. China

12.12.3. India

12.12.4. Australia & New Zealand

12.12.5. Rest of Asia Pacific

13. Latin America Lyme Disease Diagnostics Market Analysis

13.1. Latin America Lyme Disease Diagnostics Market Overview

13.2. Latin America Lyme Disease Diagnostics Market Value Share Analysis, Diagnostic Test

13.3. Latin America Lyme Disease Diagnostics Forecast, by Diagnostic Test

13.3.1. Serological Test

13.3.1.1. Elisa

13.3.1.2. Western Blot

13.3.2. Polymerase Chain Reaction (PCR) Testing

13.3.3. Immunofluorescence (IFA)

13.3.4. lymphocyte Transformation Test

13.3.5. Urine Antigen Testing

13.3.6. Others

13.4. Latin America Lyme Disease Diagnostics Market Attractiveness Analysis, by Diagnostic Test

13.5. Latin America Lyme Disease Diagnostics Market Analysis, by Sample

13.6. Latin America Lyme Disease Diagnostics Market Forecast, by Sample

13.6.1. Blood

13.6.2. Cerebrospinal Fluid (CSF)

13.6.3. Joint Fluid

13.6.4. Urine

13.7. Latin America Lyme Disease Diagnostics Market Attractiveness Analysis, by Sample

13.8. Latin America Lyme Disease Diagnostics Market Analysis, by End-user

13.9. Latin America Lyme Disease Diagnostics Market Forecast, by End-user

13.9.1. Hospitals

13.9.2. Clinical Laboratories

13.9.3. Physician Clinics

13.9.4. Others

13.10. Latin America Lyme Disease Diagnostics Market Attractiveness Analysis, by End-user

13.11. Latin America Lyme Disease Diagnostics Market Value Share and Attractiveness Analysis, by Country/Sub-region

13.12. Latin America Lyme Disease Diagnostics Market Forecast, by Country/Sub-region

13.12.1. Brazil

13.12.2. Mexico

13.12.3. Rest of Latin America

14. Middle East & Africa Lyme Disease Diagnostics Market Analysis

14.1. Middle East & Africa Lyme Disease Diagnostics Market Overview

14.2. Middle East & Africa Lyme Disease Diagnostics Market Value Share Analysis, Diagnostic Test

14.3. Middle East & Africa Lyme Disease Diagnostics Forecast, by Diagnostic Test

14.3.1. Serological Test

14.3.1.1. ELISA

14.3.1.2. Western Blot

14.3.2. Polymerase Chain Reaction (PCR) Testing

14.3.3. Immunofluorescence (IFA)

14.3.4. lymphocyte Transformation Test

14.3.5. Urine Antigen Testing

14.3.6. Others

14.4. Middle East & Africa Lyme Disease Diagnostics Market Attractiveness Analysis, by Diagnostic Test

14.5. Middle East & Africa Lyme Disease Diagnostics Market Analysis, by Sample

14.6. Middle East & Africa Lyme Disease Diagnostics Market Forecast, by Sample

14.6.1. Blood

14.6.2. Cerebrospinal Fluid (CSF)

14.6.3. Joint Fluid

14.6.4. Urine

14.7. Middle East & Africa Lyme Disease Diagnostics Market Attractiveness Analysis, by Sample

14.8. Middle East & Africa Lyme Disease Diagnostics Market Analysis, by End-user

14.9. Middle East & Africa Lyme Disease Diagnostics Market Forecast, by End-user

14.9.1. Hospitals

14.9.2. Clinical Laboratories

14.9.3. Physician Clinics

14.9.4. Others

14.10. Middle East & Africa Lyme Disease Diagnostics Market Attractiveness Analysis, by End-user

14.11. Middle East & Africa Lyme Disease Diagnostics Market Value Share and Attractiveness Analysis, by Country/Sub-region

14.12. Middle East & Africa Lyme Disease Diagnostics Market Forecast, by Country/Sub-region

14.12.1. GCC Countries

14.12.2. South Africa

14.12.3. Rest of Middle East & Africa

15. Competition Landscape

15.1. Competition Matrix

15.2. Company Profiles

15.2.1. T2 Biosystems, Inc.

15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.1.2. Financial Overview

15.2.1.3. Product Portfolio

15.2.1.4. SWOT Analysis

15.2.1.5. Strategic Overview

15.2.2. QIAGEN

15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.2.2. Product Portfolio

15.2.2.3. SWOT Analysis

15.2.2.4. Strategic Overview

15.2.3. DiaSorin S.p.A.

15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.3.2. Product Portfolio

15.2.3.3. SWOT Analysis

15.2.3.4. Strategic Overview

15.2.4. Bio-Rad Laboratories

15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.4.2. Product Portfolio

15.2.4.3. SWOT Analysis

15.2.4.4. Strategic Overview

15.2.5. Thermo Fisher Scientific, Inc.

15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.5.2. Financial Overview

15.2.5.3. Product Portfolio

15.2.5.4. SWOT Analysis

15.2.5.5. Strategic Overview

15.2.6. Trinity Biotech plc

15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.6.2. Product Portfolio

15.2.6.3. SWOT Analysis

15.2.6.4. Strategic Overview

15.2.7. IGeneX, Inc.

15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.7.2. Product Portfolio

15.2.7.3. SWOT Analysis

15.2.7.4. Strategic Overview

15.2.8. Lyme Diagnostics Ltd.

15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.8.2. Product Portfolio

15.2.8.3. SWOT Analysis

15.2.8.4. Strategic Overview

15.2.9. PerkinElmer, Inc.

15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.9.2. Product Portfolio

15.2.9.3. SWOT Analysis

15.2.9.4. Strategic Overview

15.2.10. Oxford Immunotec plc (Boulder Diagnostics)

15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.10.2. Product Portfolio

15.2.10.3. SWOT Analysis

15.2.10.4. Strategic Overview

15.2.11. Cenogenics Corporation

15.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.11.2. Product Portfolio

15.2.11.3. SWOT Analysis

15.2.11.4. Strategic Overview

15.2.12. Quest Diagnostics

15.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.12.2. Product Portfolio

15.2.12.3. SWOT Analysis

15.2.12.4. Strategic Overview

15.2.13. Ceres Nanosciences, Inc.

15.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.13.2. Product Portfolio

15.2.13.3. SWOT Analysis

15.2.13.4. Strategic Overview

15.2.14. Galaxy Diagnostics

15.2.14.1. Company Overview (HQ, Business Segments, Employee Strength)

15.2.14.2. Product Portfolio

15.2.14.3. SWOT Analysis

15.2.14.4. Strategic Overview

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111532/2900

You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333

About Us

QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.

For Latest Update Follow Us:

https://www.linkedin.com/company/qyresearch-medical/

https://www.facebook.com/QYResearch-Medical-108186514228917/

https://twitter.com/qyresearchmedi